Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4375 injection in patients with advanced solid tumors (phase I/II, open-label, single-arm, multicenter)
CTR20250004Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4375 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jan 2025; status: active.
02
Drugs
SHR-4375
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250004.